HOT” stock: CSL
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, comments on the position of CSL with regards to the impact of the Trump imposed tariffs.
Investment analysis, share recommendations, and market insights.
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, comments on the position of CSL with regards to the impact of the Trump imposed tariffs.
Beyond tariffs, I think there’s one part of the Trump Administration’s rhetoric that rewards a bit of exploration down in micro-cap world.
With Trump tariffs at this stage slugging Chinese goods with a 34% tariff, here are two exchange traded funds for investors wanting a sensible exposure to China
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says that Macquarie Group (MQG) is a buying opportunity right now.
Like many market players, I’m hoping April 2 will bring some clarity about these Trump tariffs. Collecting a few tech companies could pay dividends by the end of this year, assuming the tariff threat becomes less uncertain. Here’s what the analysts think about our quality tech companies, and I let you know my favourite plays.
James Hardie Industries (JHX) got clobbered last week, losing 20% after it announced a $14 billion takeover of The AZEK Company. Is this a buying opportunity?
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk, explains that Macquarie Group Ltd (MQG) continues to emphasise its strong long-term structural growth potential.
Here’s a look at three situations that look capable of producing good earnings growth this year – but there still looks to be value in the share price.
Because there’s no substitute for quality, investors who ‘buy this dip’ should stick to the highest-quality companies that can withstand whatever Trump throws at the global economy and geopolitical landscape. Here are two ETFs that provide exposure to the market’s best global companies.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, explains that it appears as though Telix Pharmaceuticals (TLX) is back in the uptrend and current prices are a buying opportunity.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.